Kairos Pharma announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105, a CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO in metastatic castration-resistant prostate cancer involving bone. The company said the combination targets an addressable global market of $570 million to $1.3 billion.
ENV-105 is currently being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and a Phase 2 trial for castrate resistant prostate cancer, where the company previously reported median progression-free survival of more than 13 months, presented at the 2025 ESMO Congress. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in metastatic castration-resistant prostate cancer and recently showed a 24 percent reduction in mortality risk in combination with enzalutamide in the Phase III PEACE-3 trial.
According to Kairos, CD105 is upregulated in response to standard androgen receptor inhibition and ionizing radiation, and targeting it with ENV-105 may re-sensitize resistant tumors to extend the depth and duration of response to XOFIGO.
KEY QUOTES:
“Drug resistance remains one of the greatest challenges in advanced prostate cancer, and XOFIGO, like many standard-of-care therapies, can lose efficacy over time. ENV-105 has already demonstrated the ability to re-sensitize tumors to existing treatments with a strong safety profile, and this collaboration with Bayer represents a major milestone in our mission to deliver more durable and more effective treatment regimens.”
John Yu, M.D., Chief Executive Officer, Kairos Pharma
“CD105’s role as a central resistance mechanism validated now across multiple drug classes makes this collaboration scientifically compelling and clinically timely, given XOFIGO’s recent Phase III momentum.”
Neil Bhowmick, Ph.D., Chief Scientific Officer and Principal Investigator, Kairos Pharma
